{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:13:06Z","timestamp":1793293986246,"version":"4.5.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T00:00:00Z","timestamp":1656460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>H\u00fcrthle cell carcinoma (HCC) of the thyroid is rare. There are contrasting data on its clinical behavior. The aim of this study was to describe clinic-pathological features and outcomes of HCC patients at our institution, in order to adapt our surgical management.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrospectively studied 51 cases of HCC treated at the interdisciplinary endocrine center of the University Hospital of Cologne, Germany between 2005 and 2020.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Patients median age was 63 years (range 29-78) with 64.7% of cases being female. Primary treatment included surgery and postoperative radioiodine therapy with 3.7 GBq in all patients. Surgery consisted of total thyroidectomy in all cases and additional central lymphadenectomy in 90.2% of cases. The median number of harvested lymph nodes was 11 (range 2-31). Lymph node involvement was found in two (4.3%) pT4a tumors. In all other cases (95.7%), central lymphadenectomy was prophylactic and lymph nodes were free of metastasis in final histopathology. Twelve (23.5%) patients with incomplete biochemical response to primary treatment were diagnosed with structural relapse during the course of disease, for which seven (58.4%) underwent resection of isolated cervical metastasis. Histopathology revealed soft tissue implants in all cases and cervical surgery led to biochemical and radiologic cure in only two (28.5%) cases. Five (41.6%) patients developed metastatic disease, followed by systemic therapy in two patients. Vascular invasion of the primary tumor was significantly associated with relapse (p&amp;lt;0.01).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Recurrence of HCC was common in this study. Given the low rate of lymph node metastases both in this study and in recent literature and the nature of relapse (soft tissue instead of nodal metastasis), the benefit of routine prophylactic central lymph node dissection for HCC remains unclear, especially in the absence of vascular invasion from the primary tumor.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2022.904986","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T04:44:05Z","timestamp":1656477845000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["H\u00fcrthle Cell Carcinoma: Single Center Analysis and Considerations for Surgical Management Based on the Recent Literature"],"prefix":"10.3389","volume":"13","author":[{"given":"Costanza","family":"Chiapponi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan J.M.","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Faust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane J.","family":"Bruns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Schultheis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakan","family":"Alakus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2021.1151","article-title":"Clinicopathological Characteristics and Disease-Free Survival in Patients With H\u00fcrthle Cell Carcinoma: A Multicenter Cohort Study in South Korea","volume":"36","author":"Jin","year":"2021","journal-title":"Endocrinol Metab"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2021.0424","article-title":"Follicular and Hurthle Cell Carcinoma: Comparison of Clinicopathological Features and Clinical Outcomes","volume":"32","author":"Matsuura","year":"2022","journal-title":"Thyroid"},{"key":"B3","volume-title":"Who Classification of Tumours of Endocrine Organs","author":"LIoyd","year":"2017"},{"key":"B4","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.soc.2006.05.011","article-title":"Follicular and H\u00fcrthle Cell Carcinoma of the Thyroid Gland","volume":"15","author":"Phitayakorn","year":"2006","journal-title":"Surg Oncol Clin N Am"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-019-05264-9","article-title":"Survival With Follicular and Hurthle Cell Microcarcinoma Compared to Papillary Thyroid Microcarcinoma: A Population Study of 84,532 Patients","volume":"44","author":"Khokar","year":"2020","journal-title":"World J Surg"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.surg.2013.06.029","article-title":"Hurthle Cell Carcinoma: An Update on Survival Over the Last 35 Years","volume":"154","author":"Nagar","year":"2013","journal-title":"Surgery"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1097-0347(199909)21:6<506::aid-hed2>3.0.co;2-m","article-title":"H\u00fcrthle Cell Carcinoma: A Malignancy of Low-Grade Potential","volume":"21","author":"Khafif","year":"1999","journal-title":"Head Neck"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/archotol.129.2.207","article-title":"Survival and Prognosis in H\u00fcrthle Cell Carcinoma of the Thyroid Gland","volume":"129","author":"Bhattacharyya","year":"2003","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"B9","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1186\/s12885-017-3370-x","article-title":"Survival and Prognostic Factors for Survival, Cancer Specific Survival and Disease Free Interval in 239 Patients With Hurthle Cell Carcinoma: A Single Center Experience","volume":"17","author":"Oluic","year":"2017","journal-title":"BMC Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00423-013-1057-6","article-title":"German Association of Endocrine Surgeons Practice Guideline for the Surgical Management of Malignant Thyroid Tumors","volume":"398","author":"Dralle","year":"2013","journal-title":"Langenbeck's Arch Surg"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11176","article-title":"Prognostic Factors in Patients With H\u00fcrthle Cell Neoplasms of the Thyroid","volume":"97","author":"Lopez-Penabad","year":"2003","journal-title":"Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1177\/030089160308900514","article-title":"H\u00fcrthle Cell Carcinoma: Clinic-Pathological and Biological Aspects","volume":"89","author":"Carcangiu","year":"2003","journal-title":"Tumori"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-004-7602-2","article-title":"Prognostic Indications for H\u00fcrthle Cell Cancer","volume":"28","author":"Kushchayeva","year":"2004","journal-title":"World J Surg"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2005.15.583","article-title":"Follicular Neoplasms of the Thyroid: What to Recommend","volume":"15","author":"Carling","year":"2005","journal-title":"Thyroid"},{"key":"B15","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1089\/thy.2006.16.67","article-title":"Aggressiveness of Therapy and Prognosis of Patients With H\u00fcrthle Cell Papillary Thyroid Carcinoma","volume":"16","author":"Besic","year":"2006","journal-title":"Thyroid"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.5858\/2008-132-1241-tthoca","article-title":"The Thyroid H\u00fcrthle (Oncocytic) Cell and Its Associated Pathologic Conditions: A Surgical Pathology and Cytopathology Review","volume":"132","author":"Montone","year":"2008","journal-title":"Arch Pathol Lab Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.7150\/jca.1.23","article-title":"Age and Tumor Size Predicts Lymph Node Involvement in H\u00fcrthle Cell Carcinoma","volume":"1","author":"Guerrero","year":"2010","journal-title":"J Cancer"},{"key":"B18","volume-title":"[Tnm Classification of Malignant Tumours]","author":"Wittekind","year":"2020"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1530\/EC-21-0232","article-title":"Salvage Surgery for Cervical Radioiodine Refractory 18f-Fdg-Pet Positive Recurrence of Papillary Thyroid Cancer","volume":"10","author":"Chiapponi","year":"2021","journal-title":"Endocrine Connections"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1530\/erc-19-0213","article-title":"Dynamic Risk Assessment in Patients With Differentiated Thyroid Cancer","volume":"26","author":"Pitoia","year":"2019","journal-title":"Endocrine-Related Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13246230","article-title":"Radioiodine Refractory Follicular Thyroid Cancer and Surgery for Cervical Relapse","volume":"13","author":"Chiapponi","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1210\/CLINEM\/DGAB436","article-title":"Avidity and Outcomes of Radioiodine Therapy for Distant Metastasis of Distinct Types of Differentiated Thyroid Cancer","volume":"106","author":"Sim\u00f5es-Pereira","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27770","article-title":"Hurthle Cell Carcinoma: A Population-Level Analysis of 3311 Patients","volume":"119","author":"Goffredo","year":"2013","journal-title":"Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1210\/jc.2014-1634","article-title":"Clinical and Molecular Features of H\u00fcrthle Cell Carcinoma of the Thyroid","volume":"100","author":"Chindris","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2011.0407","article-title":"Histological Patterns of Locoregional Recurrence in H\u00fcrthle Cell Carcinoma of the Thyroid Gland","volume":"22","author":"Bishop","year":"2012","journal-title":"Thyroid"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01876-7","article-title":"H\u00fcrthle Cell Carcinoma of the Thyroid Gland: Systematic Review and Meta-Analysis","volume":"38","author":"Coca-Pelaz","year":"2021","journal-title":"Adv Ther"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2016.0246","article-title":"Radioactive Iodine Treatment Is Associated With Improved Survival for Patients With H\u00fcrthle Cell Carcinoma","volume":"26","author":"Jillard","year":"2016","journal-title":"Thyroid"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/s0936-6555(03)00162-6","article-title":"External Beam Radiotherapy in the Management of Differentiated Thyroid Cancer","volume":"15","author":"Ford","year":"2003","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.696386","article-title":"Genetics, Diagnosis, and Management of H\u00fcrthle Cell Thyroid Neoplasms","volume":"12","author":"McFadden","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1530\/eje-20-0597","article-title":"Molecular Profile of H\u00fcrthle Cell Carcinomas: Recurrent Mutations in the Wnt\/\u03b2-Catenin Pathway","volume":"183","author":"Santana","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.Mct-21-0224","article-title":"Targeting the Mtor Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity","volume":"21","author":"Dong","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"B32","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/cancers13010026","article-title":"Thyroid H\u00fcrthle Cell Carcinoma: Clinical, Pathological, and Molecular Features","volume":"13","author":"Kure","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2008.06.007","article-title":"H\u00fcrthle Cell Carcinoma of the Thyroid: Retrospective Review of 62 Patients Treated at the Royal Marsden Hospital Between 1946 and 2003","volume":"35","author":"Mills","year":"2009","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.904986\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T04:44:09Z","timestamp":1656477849000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.904986\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,29]]},"references-count":33,"alternative-id":["10.3389\/fendo.2022.904986"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.904986","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,29]]},"article-number":"904986"}}